In our study, we also found that combination of AUY922 and rapamycin could more effectively downregulate KIT expression and inhibit tumor growth in IM-resistant GIST cells in vitro and in vivo compared with individual drug alone. This evidence concerns the gene KIT and gastrointestinal stromal tumor.